Article
Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy.
ESMO open - 1 Nov 2024
de Jager V D, Plomp P, Paats M S, van Helvert S, Elst A Ter, van den Berg A, Dubbink H J, van Geffen W H, Zhang L, Hendriks L E L, Hiltermann T J N, Hiddinga B I, Hijmering-Kappelle L B M, Jalving M, Kluiver J, Koopman B, van Kruchten M, van der Logt E M J, Piet B, van Putten J, Reitsma B H, Rutgers S R, de Vries M, Stigt J A, Groves M R, Timens W, Willems S M, van Kempen L C, Schuuring E, van der Wekken A J
Abstract excerpt
PURPOSE: Molecular tumor boards (MTBs) are considered beneficial for treatment decision making for patients with cancer with uncommon, rare, or complex mutational profiles. The lack of international MTB guidelines results in significant variation in practices and recommendations. Therefore, periodic follow-up is necessary to assess and govern MTB functioning. The objective of this study was to determine the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.